Travere Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $74,787 | $62,898 | $54,116 | $41,374 |
Gross Profit | 72,234 | 61,272 | 41,710 | 39,870 |
EBITDA | -45,432 | -40,820 | -56,434 | -123,087 |
EBIT | -57,523 | -52,059 | -66,779 | -132,967 |
Net Income | -60,264 | -54,811 | -70,409 | -136,061 |
Net Change In Cash | 74,787 | 62,898 | 54,116 | 41,374 |
Free Cash Flow | -45,281 | -23,768 | -52,236 | -125,471 |
Cash | 58,535 | 36,409 | 32,290 | 43,251 |
Basic Shares | 83,105 | 77,779 | 77,500 | 77,136 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $233,175 | $145,238 | $212,018 | $227,490 |
Gross Profit | 233,175 | 133,788 | 204,426 | 220,706 |
EBITDA | -265,773 | -326,246 | -299,422 | -186,679 |
EBIT | -309,328 | -364,776 | -320,141 | -213,296 |
Net Income | -321,545 | -111,399 | -278,482 | -180,091 |
Net Change In Cash | 233,175 | 145,238 | 212,018 | 227,490 |
Cost of Revenue | -101,271 | 79,268 | ||
Free Cash Flow | -338,687 | -322,280 | -214,848 | -38,943 |
Cash | 58,535 | 58,176 | 61,688 | 165,753 |
Basic Shares | 78,888 | 74,267 | 63,758 | 59,832 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.47 |
2024-09-30 | -$0.70 |
2024-06-30 | -$0.91 |
2024-03-31 | -$1.76 |
